These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 17458825

  • 1. [Immunosuppressive therapy without calcineurin inhibitors for renal transplants? Perhaps we should be cautions...].
    Fasoli G.
    G Ital Nefrol; 2007; 24(2):110. PubMed ID: 17458825
    [No Abstract] [Full Text] [Related]

  • 2. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B.
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [Abstract] [Full Text] [Related]

  • 3. The CARI guidelines. Calcineurin inhibitors in paediatric renal transplantation.
    McTaggart S, Caring for Australians with Renal Impairment (CARI).
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S106-10. PubMed ID: 17316270
    [No Abstract] [Full Text] [Related]

  • 4. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

  • 5. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M.
    Saudi J Kidney Dis Transpl; 2008 Jul 27; 19(4):564-70. PubMed ID: 18580014
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB, Karamperis N, Jørgensen KA.
    Transplant Proc; 2005 May 27; 37(4):1736-8. PubMed ID: 15919449
    [Abstract] [Full Text] [Related]

  • 7. The CARI guidelines. Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes.
    Pilmore H, Caring for Australians with Renal Impairment (CARI).
    Nephrology (Carlton); 2007 Feb 27; 12 Suppl 1():S88-97. PubMed ID: 17316287
    [No Abstract] [Full Text] [Related]

  • 8. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Bayoumy A, Sobh M, Ghoneim M.
    Iran J Kidney Dis; 2008 Jan 27; 2(1):34-9. PubMed ID: 19367007
    [Abstract] [Full Text] [Related]

  • 9. Evidence for immunosuppression in lung transplantation.
    Hopkins PM, McNeil K.
    Curr Opin Organ Transplant; 2008 Oct 27; 13(5):477-83. PubMed ID: 19060529
    [Abstract] [Full Text] [Related]

  • 10. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH, Russ GR, Chadban SJ, Campbell S, McDonald SP.
    Nephrology (Carlton); 2008 Apr 27; 13(2):171-6. PubMed ID: 18275507
    [Abstract] [Full Text] [Related]

  • 11. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L.
    G Ital Nefrol; 2008 Apr 27; 25(3):317-24. PubMed ID: 18473303
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J, Cole E, Cantarovich M.
    Clin J Am Soc Nephrol; 2007 Mar 27; 2(2):374-84. PubMed ID: 17699437
    [Abstract] [Full Text] [Related]

  • 13. Induction of the unfolded protein response by calcineurin inhibitors: a double-edged sword in renal transplantation.
    Kitamura M.
    Nephrol Dial Transplant; 2010 Jan 27; 25(1):6-9. PubMed ID: 19797334
    [No Abstract] [Full Text] [Related]

  • 14. Calcineurin nephrotoxicity.
    Williams D, Haragsim L.
    Adv Chronic Kidney Dis; 2006 Jan 27; 13(1):47-55. PubMed ID: 16412970
    [Abstract] [Full Text] [Related]

  • 15. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May 27; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

  • 16. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M.
    Transplant Proc; 2008 May 27; 40(6):1858-61. PubMed ID: 18675070
    [Abstract] [Full Text] [Related]

  • 17. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F, de Prada JA, Exposito V, García-Camarero T, Fernández-Friera L, Llano M, Ruano J, Martín-Durán R.
    J Heart Lung Transplant; 2008 Oct 27; 27(10):1135-41. PubMed ID: 18926406
    [Abstract] [Full Text] [Related]

  • 18. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 27; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 19. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A.
    Transplantation; 2007 Sep 27; 84(6):706-14. PubMed ID: 17893603
    [Abstract] [Full Text] [Related]

  • 20. [Advances in immunossuppression in liver transplantation].
    Olivera-Martínez MA.
    Rev Invest Clin; 2005 Sep 27; 57(2):237-43. PubMed ID: 16524064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.